Ardaman Shergill to Circulating Tumor DNA
This is a "connection" page, showing publications Ardaman Shergill has written about Circulating Tumor DNA.
Connection Strength
2.701
-
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 05; 8:e2300531.
Score: 0.743
-
Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. J Am Coll Surg. 2024 06 01; 238(6):1013-1020.
Score: 0.731
-
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer. Oncology (Williston Park). 2022 10 07; 36(10):620-626.
Score: 0.667
-
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
Score: 0.210
-
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118.
Score: 0.177
-
Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
Score: 0.172